A preclinical trial in mice and ferrets of an experimental mRNA vaccine against the H5 highly pathogenic avian influenza (HPAI) virus generated neutralizing antibodies and prevented severe illness and mortality of the animals.
Ventyx Biosciences Inc. has released promising preclinical data for its CNS-penetrant NLRP3 inhibitor VTX-3232 in murine diet-induced obesity (DIO) models.
Researchers from Septerna Inc. presented the discovery and preclinical characterization of novel parathyroid hormone PTH1 receptor (PTH1R) agonists being developed as a new treatment option against hypoparathyroidism.
The ongoing European Association for the Study of the Liver 2024 congress in Milan opened yesterday with several presentations on cell plasticity and its role in liver function and regeneration in chronic liver disease situations.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described serine/threonine-protein kinase ULK1 inhibitors reported to be useful for the treatment of cancer.
Scientists at Korea Research Institute of Chemical Technology and Oncord Bio Inc. have divulged molecular glue degraders targeting protein cereblon (CRBN) and acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer, graft-vs.-host disease, leprosy and inflammatory disorders.
Nikang Therapeutics Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2) targeting moiety through a linker reported to be useful for the treatment of cancer.
Ribometrix Inc. has synthesized eukaryotic translation initiation factor 4E (eiF4E) inhibitors reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders and allergy.
RSS
